Latest filings (excl ownership)
8-K
Neurotrope and Metuchen Pharmaceuticals Announce Completion of
7 Dec 20
25-NSE
Exchange delisting
2 Dec 20
8-K
Submission of Matters to a Vote of Security Holders
25 Nov 20
DEFA14A
Additional proxy soliciting materials
24 Nov 20
8-K
Other Events
24 Nov 20
DEFA14A
Additional proxy soliciting materials
20 Nov 20
8-K
Neurotrope, Inc. Approves Spin-Off of Neurotrope
20 Nov 20
10-Q
2020 Q3
Quarterly report
9 Nov 20
DEFM14A
Proxy related to merger
2 Nov 20
425
Business combination disclosure
30 Sep 20
8-K
Other Events
30 Sep 20
425
Business combination disclosure
30 Sep 20
8-K
Entry into a Material Definitive Agreement
30 Sep 20
10-Q
2020 Q2
Quarterly report
10 Aug 20
8-K
Entry into a Material Definitive Agreement
29 Jul 20
8-K
Other Events
24 Jul 20
425
Business combination disclosure
24 Jul 20
425
Business combination disclosure
24 Jul 20
8-K
Entry into a Material Definitive Agreement
24 Jul 20
10-Q
2020 Q1
Quarterly report
12 Jun 20
8-K
Conference Call Transcript
28 May 20
425
Business combination disclosure
28 May 20
8-K
Entry into a Material Definitive Agreement
18 May 20
425
Business combination disclosure
18 May 20
8-K
Other Events
11 May 20
EFFECT
Notice of effectiveness
27 Apr 20
424B2
Prospectus for primary offering
24 Apr 20
CORRESP
Correspondence with SEC
22 Apr 20
UPLOAD
Letter from SEC
22 Apr 20
S-3
Shelf registration
17 Apr 20
10-K
2019 FY
Annual report
13 Mar 20
8-K
Departure of Directors or Certain Officers
27 Feb 20
8-K
Regulation FD Disclosure
26 Feb 20
424B5
Prospectus supplement for primary offering
23 Jan 20
8-K
Neurotrope, Inc. Announces $18 Million Registered Direct Offering
23 Jan 20
8-K
Neurotrope Provides Corporate Update After Completing Bryostatin-1 Data Analysis for Advanced Alzheimer’s Disease Trial
22 Jan 20
8-K
Other Events
21 Jan 20
10-Q
2019 Q3
Quarterly report
12 Nov 19
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
25 Oct 19
8-K
Entry into a Material Definitive Agreement
25 Oct 19
Latest ownership filings
SC 13G/A
INTRACOASTAL CAPITAL, LLC
29 Jan 21
4
Ivan P. Gergel
3 Dec 20
4
George Perry
3 Dec 20
4
Daniel L. Alkon
3 Dec 20
4
Charles S. Ryan
3 Dec 20
4
Bruce Bernstein
3 Dec 20
4
William S. Singer
3 Dec 20
4
ROBERT WEINSTEIN
3 Dec 20
4
Joshua Silverman
3 Dec 20
4
JONATHAN SCHECHTER
3 Dec 20
4
Ivan P. Gergel
27 Nov 20
4
George Perry
27 Nov 20
4
Daniel L. Alkon
27 Nov 20
4
Charles S. Ryan
27 Nov 20
4
Bruce Bernstein
27 Nov 20
4
William S. Singer
27 Nov 20
4
ROBERT WEINSTEIN
27 Nov 20
4
Joshua Silverman
27 Nov 20
4
JONATHAN SCHECHTER
27 Nov 20
4
JONATHAN SCHECHTER
2 Nov 20
4
JONATHAN SCHECHTER
26 Oct 20
4
JONATHAN SCHECHTER
22 Oct 20
4
Joshua Silverman
20 Oct 20
4
Joshua Silverman
19 Oct 20
4
Ivan P. Gergel
24 Mar 20
4
Joshua Silverman
24 Mar 20
4
JONATHAN SCHECHTER
24 Mar 20
4
Bruce Bernstein
24 Mar 20
4
William S. Singer
24 Mar 20
4
George Perry
24 Mar 20
SC 13G/A
Beneficial ownership report (amended)
14 Feb 20
SC 13G/A
Beneficial ownership report (amended)
12 Feb 20
SC 13G
Neurotrope, Inc.
31 Jan 20
4
Charles S. Ryan
16 Dec 19
SC 13G
Neurotrope, Inc.
30 Aug 19
4
Michael Ciraolo
16 Apr 19
4
William S. Singer
15 Apr 19
4
Ivan P. Gergel
15 Apr 19
4
James Gottlieb
15 Apr 19
4
Shana Phares
15 Apr 19